drugset
drugset / Trial / NCT06988670

A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

NCT06988670 ↗

Phase 2 Recruiting 35 enrolled Extend Biosciences Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.

Timeline

Start
2025-05-05
Primary completion
2027-05
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject EXT608 Unknown 50 ug Subcutaneous

Indications

hypoparathyroidism